NCT05088889
Clinical Trial Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT05088889 |
| Title | Maintenance Ipilimumab + Nivolumab Post Induction Chemotherapy + SBRT for First Line Treatment Stage IV Pancreatic Cancer |
| Recruitment | Unknown status |
| Gender | both |
| Phase | Phase I |
| Variant Requirements | Yes |
| Sponsors | Sheba Medical Center |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | ISR |
CKB BOOST